AZ TO SELL ANTIBIOTICS BUSINESS TO PFIZER This announcement

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
AZ TO SELL ANTIBIOTICS BUSINESS TO PFIZER

This announcement contains inside information 24 August 2016 07:00 ASTRAZENECA TO SELL SMALL MOLECULE ANTIBIOTICS BUSINESS TO PFIZER Value-creating divestment supports AstraZeneca’s focus on three main therapy areas Pfizer’s dedicated focus on infectious diseases will extend the reach of the antibiotics to more patients globally and maximise the potential of the late-stage, small molecule antibiotics business AstraZeneca today announced that it has entered into an agreement with Pfizer Inc. (Pfizer) to sell the commercialisation and development rights to its late -stage small molecule antibiotics business in most markets globally outside the US*. The agreement reinforces AstraZeneca’s focus on developing transformational medicines in its three main therapy areas, while realising value from the strong portfolio of established and late-stage small molecule antibiotics through Pfizer’s dedicated commercialisation and development capabilities in anti -infectives. The portfolio comprises the approved antibiotics Merrem, Zinforo and Zavicefta, and ATM-AVI and CXL, which are in clinical development. Under the terms of the agreement, Pfizer will make an upfront payment to AstraZeneca of $550 million upon completion and a further unconditional payment of $175 million in January 2019 for the commercialisation and development rights to the late-stage antibiotics business in all markets where AstraZeneca holds the rights. In addition, Pfizer will pay up to $250 million in commercial, manufacturing and regulatory milestones, up to $600 million in sales-related payments as well as recurring, double-digit royalties on future sales of Zavicefta and ATM-AVI in certain markets. Luke Miels, Executive Vice President for Europe and Head of the Antibiotics Business Unit at AstraZeneca, said: “This agreement reinforces our strategic focus to invest in our three main therapy areas where we can make the greatest difference to patients’ lives. We’re pleased that our strong science in antibiotics will continue to serve a critical public health need through Pfizer’s dedicated focus on infectious diseases, ensuring these important medicines reach greater numbers of patients around the world.” John Young, Group President, Pfizer Essential Health, said: “As we continue to reshape our Essential Health portfolio, we are focusing on areas that further address global public health needs and that complement our core capabilities and experience in therapeutic areas, including anti-infectives. We are committed to looking for ways to enhance our portfolio around the world where we offer patients and healthcare professionals access to more than 60 anti-infective and anti-fungal medicines. The addition of AstraZeneca’s complementary small molecule anti-infectives portfolio will help expand patient access to these important medicines and enhance our global expertise and offerings in this increasingly important area of therapeutics, in addition to providing the opportunity for near-term revenue growth.” MedImmune’s portfolio of biologics, on-market products such as FluMist/Fluenz and Synagis, and AstraZeneca’s stake in Entasis Therapeutics, spun-off from AstraZeneca in 2015 and now operating as a stand-alone company focused on the development of innovative small-molecule anti-infectives, are not included as part of the agreement. Financial considerations The agreement with Pfizer is expected to close in the fourth quarter of 2016, subject to customary closing conditions. As AstraZeneca will de-recognise an intangible product asset and does not maintain a significant future interest in the late-stage small molecule antibiotics business all payments will be reported as Other Operating Income in the Company’s financial statements. This includes the upfront payment of $550 million and unconditional payment of $175 million in 2019 (both to be recognised net of the aforementioned product intangible in 2016), the milestones of up to $250 million, the sales-related payments of up to $600 million and the recurring double-digit royalties on sales of Zavicefta and ATM-AVI. AstraZeneca’s established antibiotic medicines Merrem and Zinforo are available in more than 100 countries and generated Product Sales in 2015 of $250 million. The agreement does not impact AstraZeneca’s financial guidance for 2016. About AstraZeneca’s small molecule anti-infective business +--------------+-------------------------------------------------------------+ |Medicine |Indication | +--------------+-------------------------------------------------------------+ |Merrem/Meronem|Merrem/Meronem is a   carbapenem anti-bacterial used for the | |(meropenem) |treatment of serious infections in   hospitalised patients. | | |Meropenem is a broad-spectrum agent, originally created   by | | |Sumitomo Dainippon Pharma Co., Ltd. and indicated for the | | |treatment of a   wide variety of serious bacterial infections| | |in adults and children,   including pneumonia, community | | |-acquired pneumonia and nosocomial pneumonia;   broncho | | |-pulmonary infections in cystic fibrosis; complicated urinary| | |tract   infections; complicated intra-abdominal infections; | | |intra- and post-partum   infections; complicated skin and | | |soft tissue infections; and acute bacterial   meningitis in | | |adults and children over 3 months of age. In the US, Merrem | | |is indicated as single-agent   therapy for the treatment of | | |intra-abdominal infections and bacterial   meningitis when | | |caused by susceptible strains of the designated   | | |microorganisms in adult and paediatric patients.*AstraZeneca | | |  holds the global rights to commercialise Merrem,   with the| | |exception of Japan,   China, Taiwan and Korea, where the | | |rights are held by Sumitomo Dainippon Pharma Co., Ltd. In | | |addition, Sumitomo   Dainippon Pharma has an option to | | |commercialise the product in   Thailand, Singapore, Vietnam, | | |Malaysia, Philippines, Indonesia and Hong Kong. | +--------------+-------------------------------------------------------------+ |Zinforo |Zinforo was launched in October 2012 and is an intravenous   | |(ceftaroline |cephalosporin antibiotic intended for use as a monotherapy in| |fosamil) |the treatment   of adult patients with complicated skin and | | |soft tissue infections (cSSTI) or   community-acquired | | |pneumonia (CAP). Zinforo is bactericidal and works by binding| | |to and   inhibiting penicillin-binding proteins (PBPs). | | |Zinforo has been designed with a specific and novel mode   of| | |action which contributes to its bactericidal activity against| | |the common   causative pathogens of cSSTI, and CAP and unlike| | |other cephalosporins, shows   a high affinity for particular | | |PBPs in MRSA. Zinforo has now been approved in 52 markets and| | |launched in 32   markets.*AstraZeneca   holds the global | | |rights to commercialise Zinforo,   with the exception of | | |North America and Japan, where the rights are held by | | |Allergan   Pharmaceutical Industries Limited and Takeda   | | |Pharmaceutical Company Limited Respectively. | +--------------+-------------------------------------------------------------+ |Zavicefta |Zavicefta is a combination antibiotic that has been   | |(ceftazidime |developed to treat serious Gram-negative bacterial | |-avibactam) |infections. It consists of   a combination of avibactam and | | |ceftazidime - a third-generation   antipseudomonal | | |cephalosporin with a well-established efficacy and safety   | | |profile. Avibactam (AVI, NXL104) is a first-in-class broad | | |-spectrum   β-lactamase inhibitor, which protects ceftazidime| | |against degradation by   Class A, C and some D, β-lactamases.| | |The addition of avibactam to ceftazidime   protects | | |ceftazidime from breakdown by β-lactamases. Zavicefta offers | | |a differentiated profile versus existing   treatment options | | |in serious Gram-negative infections through its coverage of  | | |a broad range of species of Enterobacteriaceae   including | | |those that produce extended-spectrum   beta-lactamase and | | |Klebsiella pneumoniae carbapenemase, together with activity  | | |against difficult-to-treat P.   aeruginosa.*AstraZeneca   | | |holds the global rights to commercialise Zavicefta,   with | | |the exception of North America, where the rights are held by | | |Allergan   Pharmaceutical Industries Limited. | +--------------+-------------------------------------------------------------+ |ATM-AVI |ATM-AVI is a   bactericidal, injectable combination of | | |aztreonam (ATM) and a β-lactamase inhibitor, Avibactam (AVI, | | |  NXL104), which is in development for the treatment of life | | |-threatening   Gram-negative bacterial infections caused by | | |multi-drug resistant (MDR)   strains, including infections | | |caused by metallo-beta-lactamase   (MBL)-producing pathogens.| | |ATM-AVI has the potential to be a replacement for,   or | | |alternative to, existing antibacterial agents, including | | |colistin and   tigecycline. ATM-AVI has completed its Phase I| | |studies and is currently in Phase   II | | |development.*AstraZeneca   holds the global rights to | | |commercialise ATM-AVI, with the exception of North   America,| | |where the rights are held by Allergan Pharmaceutical | | |Industries   Limited. | +--------------+-------------------------------------------------------------+ |CXL |CXL is a novel, injectable bactericidal   β-lactam/β | | |-lactamase inhibitor combination of ceftaroline fosamil | | |(marketed   as Zinforo in AstraZeneca markets),   a next | | |-generation cephalosporin with activity against multidrug | | |-resistant   Gram-positive and common enteric Gram-negative | | |pathogens, and Avibactam (AVI,   NXL104), a potent β | | |-lactamase inhibitor that inhibits Ambler Class A   | | |(including ESBL producers and KPC carbapenemases), Class C | | |(Amp C)   β-lactamase enzymes, and some Class D β-lactamase | | |enzymes. CXL has completed   a Phase II study and is ready | | |for progression into Phase III.*AstraZeneca   holds the | | |global rights to commercialise CXL, with the exception of | | |North   America, where the rights are held by Allergan | | |Pharmaceutical Industries   Limited. | +--------------+-------------------------------------------------------------+ About Pfizer Inc. At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety, and value in the discovery, development, and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments, and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments, and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more, please visit us at www.pfizer.com. In addition, to learn more, follow us on Twitter at @Pfizer and @Pfizer_News, LinkedIn, and like us on Facebook at Facebook.com/Pfizer. About AstraZeneca AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Respiratory & Autoimmunity, Cardiovascular & Metabolic Diseases, and Oncology. The Company is also active in inflammation, infection and neuroscience through numerous collaborations. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com CONTACTS Media   Enquiries Esra Erkal-Paler UK/Global +44 203 749 5638 Vanessa Rhodes UK/Global +44 203 749 5736 Karen Birmingham UK/Global +44 203 749 5634 Rob Skelding UK/Global +44 203 749 5821 Jacob Lund Sweden +46 8 553 260 20 Michele Meixell US +1 302 885 2677 Investor Relations UK Thomas Kudsk Larsen +44 203 749 5712 Craig Marks Finance,   Fixed Income, M&A +44 7881 615 764 Nick Stone Respiratory   & Autoimmunity +44 203 749 5716 Henry Wheeler Oncology +44 203 749 5797 Christer Gruvris Infection & Neuroscience +44 203 749 5711 US Lindsey Trickett Cardiovascular & Metabolic Diseases +1 240 543 7970 Mitchell Chan Oncology +1 240 477 3771 Toll free +1 866 381 7277 Adrian Kemp Company Secretary AstraZeneca PLC -ENDS-

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 731

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 410

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 137

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 303

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 398

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 348

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 386

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 445

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 530

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 666

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading

Top 5 Most Recently Viewed Articles

Axis Auto Finance's Strategic Asset Sale to Fionic Canada Ltd.

Updated Category News Views 269

Axis Auto Finance Announces Significant Asset Sale Axis Auto Finance Inc. is on the cusp of a major transformation. The Company, recognized for providing innovative auto financing solutions, has entered into an asset purchase agreement with Fionic Canada Ltd. and its affiliates for the sale of its auto finance business. This agreement marks a pivotal moment for Axis as it...

Continue Reading
Investors Anticipate Earnings Report for Brixmor Property Group

Updated Category News Views 144

Anticipating Earnings from Brixmor Property Group Brixmor Property Group (NYSE: BRX) is set to reveal its quarterly earnings, igniting curiosity and hope among investors. With expectations high, many are eager to see if the company can surpass estimates and provide encouraging guidance for the upcoming quarter. Expected Earnings Per Share Analysts are predicting an...

Continue Reading
Growing Demand for Tympanostomy Products: Market Insights

Updated Category News Views 115

Overview of the Tympanostomy Products Market The global tympanostomy products market is anticipated to flourish, driven significantly by the increasing prevalence of ear infections and heightened awareness regarding ear health. This surge reflects a broader trend in modern healthcare where innovative solutions are being sought to tackle persistent health issues. Market...

Continue Reading
Enhancing Global Climate Data with WIS 2.0 Test Infrastructure

Updated Category News Views 161

Revolutionizing Environmental Data Access Synoptic Data, a leading Public Benefit Corporation, has embarked on an exciting journey to enhance global environmental data with the development of the WIS 2.0 Test Infrastructure. This initiative arises from the pressing need for dependable and real-time environmental observations, particularly for regions that have...

Continue Reading
DTF Tax-Free Income Fund Outlines New Dividend Payments

Updated Category News Views 75

DTF Tax-Free Income 2028 Term Fund Inc. Readies for Dividend Payments The Board of Directors of DTF Tax-Free Income 2028 Term Fund Inc. (NYSE: DTF), a closed-end fund, has declared upcoming dividend payments for its common stock. This decision underscores the Fund's dedication to providing its investors with steady income through carefully curated portfolios of tax-exempt...

Continue Reading